Becton, Dickinson and Company $BDX Shares Sold by Addenda Capital Inc.

Addenda Capital Inc. decreased its holdings in Becton, Dickinson and Company (NYSE:BDX) by 49.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 8,274 shares of the medical instruments supplier’s stock after selling 7,947 shares during the quarter. Addenda Capital Inc.’s holdings in Becton, Dickinson and Company were worth $1,425,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of BDX. Brighton Jones LLC raised its holdings in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 877 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Becton, Dickinson and Company by 50.6% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier’s stock worth $18,808,000 after buying an additional 27,581 shares in the last quarter. FORA Capital LLC bought a new position in shares of Becton, Dickinson and Company during the 1st quarter worth about $3,458,000. Foster Victor Wealth Advisors LLC purchased a new position in Becton, Dickinson and Company in the 1st quarter valued at approximately $6,406,000. Finally, GAMMA Investing LLC lifted its stake in Becton, Dickinson and Company by 29.9% in the first quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier’s stock worth $744,000 after purchasing an additional 748 shares during the last quarter. 86.97% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Argus lifted their price objective on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Royal Bank Of Canada assumed coverage on shares of Becton, Dickinson and Company in a research report on Thursday. They issued a “sector perform” rating and a $211.00 price objective for the company. Barclays decreased their target price on Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating for the company in a research report on Tuesday, June 3rd. Morgan Stanley lifted their target price on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Finally, Wells Fargo & Company upped their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research report on Friday, August 8th. Four investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $213.09.

Becton, Dickinson and Company Trading Up 2.2%

NYSE:BDX opened at $184.59 on Friday. The company has a market capitalization of $52.91 billion, a P/E ratio of 33.20, a PEG ratio of 1.49 and a beta of 0.27. The firm has a fifty day simple moving average of $188.27 and a 200-day simple moving average of $188.72. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, topping the consensus estimate of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.50 billion. During the same quarter in the previous year, the firm posted $3.50 earnings per share. The company’s quarterly revenue was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be given a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 74.82%.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the business’s stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director owned 22,226 shares in the company, valued at approximately $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Michael David Garrison sold 1,185 shares of the firm’s stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president owned 4,887 shares in the company, valued at approximately $881,077.23. This trade represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 2,965 shares of company stock worth $551,536 in the last 90 days. Company insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.